All filters
Slidesets
Controlling HBsAg as a Key Component of a Combination Strategy to Affect an HBV Cure- Michael Sofia, PhD
Presented at:
HEP DART 2017
Slidesets
Eliminating HCV Transmission by Enhancing Care and Treatment Among HCV/HIV Co-infected Individuals in Australia (not available)- Joseph Doyle, MD
Presented at:
HEP DART 2017
Slidesets
Management of HCV in Decompensated liver disease- Michael Manns
Presented at:
HEP DART 2017
Slidesets
DAA Controversies: Do they Cause HBV Reactivation and/or HCC?- Jordan Feld, MD, MPH
Presented at:
HEP DART 2017
Slidesets
Pan-genotypic direct-acting antiviral agents: Opportunity to achieve HCV elimination- Tarik Asselah
Presented at:
HEP DART 2017
Slidesets
When are we done? How long do we follow patients with advanced fibrosis or cirrhosis after SVR? (not available)- Paul Pockros
Presented at:
HEP DART 2017
Slidesets
A Next Generation HBV Capsid Inhibitor, AB-506: In Vitro and In Vivo Antiviral Characterization- Dr. N. Mani
Presented at:
HEP DART 2017
Slidesets
NASH Globally: Pathways to Combination Therapy, Biomarkers and Outcomes- Arun Sanyal
Presented at:
HEP DART 2017
Slidesets
Predicting Susceptibility and Resistance for Hepatitis B Virus Capsid Assembly Effectors- Dr. B. Cox
Presented at:
HEP DART 2017
Slidesets
Evolving Role of Real-World Evidence in NASH and HCC: From Bench to Poolside (not available)- Michael Fried
Presented at:
HEP DART 2017
Slidesets
The Re-vival of Bile Acid Based Therapeutics for Children and Adults- Saul Karpen
Presented at:
HEP DART 2017
Slidesets
Update on Prophylactic HCV Vaccine Development- Andrea Cox, MD
Presented at:
HEP DART 2017
Slidesets
Hepatitis B virus splice variants are associated with and predictive of Liver cancer- Dr. P. Revill
Presented at:
HEP DART 2017
Slidesets
Seroclearance of HBsAg in Chronic Hepatitis B Virus Patients on Lamivudine, Tenofovir or Entecavir Therapy: A 10 Year Experience- Dr. S. Ono
Presented at:
HEP DART 2017
Slidesets
Lessons learned towards a Vaccine and Functional Cure for HIV (not available)- Mario Stevenson
Presented at:
HEP DART 2017
Slidesets
Liver Directed Acetyl-CoA Carboxylase Inhibitor GS-0976 For NASH (not available)- Adrian Ray
Presented at:
HEP DART 2017
Slidesets
The Effectiveness of Treatment for Chronic Hepatitis C (and Hepatitis B) in Pediatric Populations- Manal El-Sayed, MD, PhD
Presented at:
HEP DART 2017
Slidesets
Aramchol for NASH and beyond: From scientific rationale to clinical development- Carol Brosgart
Presented at:
HEP DART 2017